I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
4.090
+0.190 (4.87%)
At close: Sep 12, 2025, 4:00 PM EDT
4.080
-0.010 (-0.24%)
After-hours: Sep 12, 2025, 6:40 PM EDT
I-Mab Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
470.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | -140.75% |
| Dec 31, 2022 | -1.55M | -15.41M | -111.19% |
| Dec 31, 2021 | 13.86M | -222.44M | -94.14% |
| Dec 31, 2020 | 236.29M | 231.99M | 5,384.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IMAB News
- 2 days ago - I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market - Seeking Alpha
- 19 days ago - I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - GlobeNewsWire
- 23 days ago - I-Mab to Participate in September Investor Conferences - GlobeNewsWire
- 6 weeks ago - Everest Medicines Expands Strategic Investment in I-MAB - PRNewsWire
- 6 weeks ago - I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health - GlobeNewsWire
- 2 months ago - I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 2 months ago - I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - GlobeNewsWire